scholarly journals A pilot study of a culturally-appropriate, educational intervention to increase participation in cancer clinical trials among African Americans and Latinos

2021 ◽  
Author(s):  
Jennifer Cunningham-Erves ◽  
Tilicia L. Mayo-Gamble ◽  
Pamela C. Hull ◽  
Tao Lu ◽  
Claudia Barajas ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Pilot Study ◽  
African Americans ◽  
Educational Intervention ◽  
Cancer Clinical Trials ◽  
Culturally Appropriate

scholarly journals Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years

2018 ◽  
Vol 14 (1) ◽  
pp. e1-e10 ◽  
Author(s):  
Narjust Duma ◽  
Jesus Vera Aguilera ◽  
Jonas Paludo ◽  
Candace L. Haddox ◽  
Miguel Gonzalez Velez ◽  
...  
Keyword(s):  
Clinical Trials ◽  
African Americans ◽  
Historical Data ◽  
The Elderly ◽  
Cancer Clinical Trials ◽  
Specific Patient ◽  
The Past ◽  
Therapeutic Trials ◽  
Oncology Clinical Trials ◽  
Enrollment Data

Purpose: Many cancer clinical trials lack appropriate representation of specific patient populations, limiting their generalizability. Therefore, we determined the representation of ethnic minorities and women in cancer clinical trials. Methods: Enrollment data from all therapeutic trials reported as completed in ClinicalTrials.gov from 2003 to 2016 were analyzed. We calculated enrollment fractions (EFs) for each group, defined as the number of enrollees divided by the 2013 Surveillance, Epidemiology, and End Results (SEER) database cancer prevalence. Results: Of 1,012 clinical trials, 310 (31%) reported ethnicity with a total of 55,689 enrollees. Participation varied significantly across ethnic groups. Non-Hispanic whites were more likely to be enrolled in clinical trials (EF, 1.2%) than African Americans (EF, 0.7%; P < .001) and Hispanics (EF, 0.4%; P < .001). A decrease in African American (6% v 9.2%) and Hispanic (2.6% v 3.1%) enrollment was observed when compared with historical data from 1996 to 2002. Younger patients (age younger than 65 years) were more likely to be enrolled in clinical trials than the elderly (64% v 36%; P < .001). Low recruitment of female patients was observed in clinical trials for melanoma (35%), lung cancer (39%), and pancreatic cancer (40%). Conclusion: We observed a decrease in recruitment of minorities over the past 14 years compared with historical data. African Americans, Hispanics, and women were less likely to be enrolled in cancer clinical trials. Future trials should take extra measures to recruit participants that adequately represent the US cancer population.

scholarly journals Pilot Study of a Point-of-use Decision Support Tool for Cancer Clinical Trials Eligibility

1999 ◽  
Vol 6 (6) ◽  
pp. 466-477 ◽  
Author(s):  
P. P. Breitfeld ◽  
M. Weisburd ◽  
J. M. Overhage ◽  
G. Sledge ◽  
W. M. Tierney
Keyword(s):  
Clinical Trials ◽  
Decision Support ◽  
Pilot Study ◽  
Decision Support Tool ◽  
Cancer Clinical Trials ◽  
Support Tool ◽  
Point Of Use

scholarly journals The Systemic Exclusion of Native Americans from Cancer Clinical Trials.

2021 ◽  
Author(s):  
Joseph Angel De Soto ◽  
Gabriel Selassie ◽  
Gilberta Yazzie
Keyword(s):  
Health Care ◽  
Clinical Trials ◽  
Native American ◽  
African Americans ◽  
Native Americans ◽  
Ethnic Minorities ◽  
Health Care Disparities ◽  
The United States ◽  
Cancer Clinical Trials ◽  
Unnecessary Death

Introduction: A major source of health care disparities derives from the underrepresentation of ethnic minorities in clinical trials. The inclusion of ethnic minorities is necessary to generalize the results in terms of efficacy and toxicology of medications in cancer treatment. Methodology: In this retrospective study, 80 cancer clinical trials with an aggregate of 278,470 participants performed within the last ten years were selected at random. The number of ethnic minorities participating and inclusion of them in the results were evaluated. Results: Only, 42.5% of cancer clinical trials reported the ethnic background of participants in their trials while even less 5% reported the efficacy or toxicology of the therapeutic intervention for ethnic minorities. Whites, Hispanics, African Americans, and Native Americans make up 60.1%, 18.5%, 13.4% and 1.5% of the population they made up 85.3%, 2.54%, 7.6% and 0.12% of the participants that reported ethnicity, respectively. Out of 278,470 participants in cancer clinicals trials only 133 (0.048%) could be identified as Native American . Conclusion: Native Americans were nearly completely excluded from cancer clinical trials. African Americans and Hispanics were greatly underrepresented. Cancer Clinical trials may not be generalizable and have been inherently racist in the United States. This has led to the unnecessary death and suffering of Native Americans from cancer.

scholarly journals A Pilot Study of a Culturally-Appropriate, Educational Intervention to Increase Participation in Cancer Clinical Trials Among African Americans and Latinos

2021 ◽  
Author(s):  
Jennifer Cunningham-Erves ◽  
Tilicia Mayo-Gamble ◽  
Pamela C Hull ◽  
Tao Lu ◽  
Claudia Barajas ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
African Americans ◽  
Educational Program ◽  
Trial Participation ◽  
Willingness To Participate ◽  
Culturally Appropriate ◽  
Clinical Trial Participation ◽  
Medical Researchers ◽  
Town Halls

Abstract Aim: Culturally-appropriate, educational programs are recommended to improve cancer clinical trial participation among African Americans and Latinos. This study investigated the effect of a culturally-appropriate, educational program on knowledge, trust in medical researchers, and intent for clinical trial participation among African Americans and Latinos in Middle Tennessee.Method: Trained community health educators delivered a 30-minute presentation with video testimonials to 198 participants in 13 town halls. A pre-post survey design was used to evaluate the intervention among 102 participants who completed both pre- and post-surveys one to two weeks after the session. Results: Paired-sample t-test showed significant increases in unadjusted mean scores for knowledge (p < .001), trust in medical researchers (p < .001), and willingness to participate in clinical trials (p = .003) after the town halls in the overall sample. After adjusting for gender and education, all three outcomes remained significant for the overall sample (knowledge: p < .001; trust in medical researchers: p < .001; willingness: p = .001) and for African Americans (knowledge: p < .001; trust in medical researchers: p = .007; willingness: p = .005). However, willingness to participate was no longer significant for Latinos (knowledge: p < .001; trust in medical researchers: p = .034; willingness: p = .084).Conclusions: The culturally-appropriate, educational program showed promising results for short-term, clinical trial outcomes. Further studies should examine efficacy to improve research participation outcomes.

Open to options: A cancer clinical trials education pilot study

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 6116-6116
Author(s):  
E. H. Weiss ◽  
M. Golant ◽  
A. Thornton ◽  
V. Kennedy ◽  
E. Stovall ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Pilot Study ◽  
Cancer Clinical Trials

Open to options: A cancer clinical trials education pilot study

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 6116-6116
Author(s):  
E. H. Weiss ◽  
M. Golant ◽  
A. Thornton ◽  
V. Kennedy ◽  
E. Stovall ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Pilot Study ◽  
Cancer Clinical Trials
Sign in / Sign up

Export Citation Format

Share Document